tracken
Aurinia Pharmaceuticals Inc. Aktie News
Positiv
The Motley Fool
●
4 Tage alt
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
San Diego-based Tang Capital Management increased its position in AUPH by 1.3 million shares in the third quarter. Following the transaction, Tang reported holding more than 11.3 million AUPH shares valued at $125.2 million.
Neutral
Seeking Alpha
●
etwa ein Monat alt
Aurinia Pharmaceuticals Inc. ( AUPH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Peter Greenleaf - President, CEO & Director Joseph Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Resear...
Neutral
Business Wire
●
etwa ein Monat alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2025, total revenue was $73.5 million and $205.9 million, up 8% and 17%, re...
Neutral
Seeking Alpha
●
etwa ein Monat alt
Aurinia Pharmaceuticals (AUPH) files a federal lawsuit against FDA's George Tidmarsh for alleged false statements about its lupus nephritis drug. Baidu's (BIDU) Apollo Go robotaxi service matches Waymo's weekly ride volume, while Pony AI (PONY) prepares for a major Hong Kong IPO.
Neutral
Business Wire
●
etwa ein Monat alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia's management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the...
Positiv
Seeking Alpha
●
etwa ein Monat alt
Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development. AUPH's Lupkynis leads as the first FDA-approved oral therapy for lupus nephritis, with 22% YoY revenue growth and expanding physician adoption. The company's pipeline drug, AUR200, targets dual immune proteins and offers long-term diversification potential in ...
Neutral
Business Wire
●
etwa 2 Monate alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.
Neutral
Business Wire
●
2 Monate alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Responds to Now Retracted LinkedIn Post.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
